论文部分内容阅读
[目的]本课题研究注射器驱动泵(微泵,syringe driver/micro-pump)联合用药连续皮下输注(Continuous subcutaneous infusion,CSCI),以缓解晚期癌症患者的疼痛、控制其他难治性痛苦症状,为建立我国姑息医学模式及治疗指南提供科学的依据。[方法]选择40例疼痛评分≥7分、预期生存期≥30d、伴有其他难治性痛苦症状的晚期癌症患者,随机分为2组,每组20例;采用交叉设计的方差分析方法,分别先后给予口服盐酸吗啡缓释片和使用微泵联合用药,采用SPSS13.0统计软件分析。[结果]比较微泵皮下给予吗啡与口服吗啡的疼痛减轻分值和不良反应发生率,P﹤0.05,差异有统计学意义。微泵联合用药控制疼痛及其他痛苦症状的缓解率优于口服联合用药。[结论]微泵联合用药的镇痛治疗效果优于口服吗啡缓释片,不良反应较少,能较好的控制晚期癌症患者的疼痛和其他痛苦症状。
[Objective] The purpose of this study was to investigate the effects of syringe driver / micro-pump (CSA) on continuous subcutaneous infusion (CSCI) to relieve the pain of patients with advanced cancer and to control other intractable painful symptoms. To provide a scientific basis for the establishment of palliative medicine model and treatment guidelines. [Methods] Forty patients with advanced cancer with pain score> = 7 and expected life span> = 30d with other intractable painful symptoms were randomly divided into two groups with 20 patients in each group. Cross-analysis of variance They were given oral morphine hydrochloride sustained-release tablets and the use of micro-pump combination therapy, using SPSS13.0 statistical software analysis. [Results] Compared with the subcutaneous injection of morphine and oral morphine pain relief score and the incidence of adverse reactions, P <0.05, the difference was statistically significant. The combination of micro-pump control of pain and other pain relief symptoms than oral combination therapy. [Conclusion] The combination of micro-pump analgesic therapy is superior to oral morphine sustained-release tablets, less adverse reactions, can better control the pain and other pain symptoms of advanced cancer patients.